Clinical trials
Relapsed Large B-cell Lymphoma clinical trials
Below are recruiting relapsed large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 239 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04223765RecruitingPhase 1
Testing a new CAR T-cell treatment for kappa cancers
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT06132503RecruitingPhase 1
Testing LP-284 for advanced lymphomas and solid tumors
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
West Valley City, UtahAges 18 years+ - NCT05351593RecruitingPhase 1/Phase 2
Tafasitamab and lenalidomide for returning CNS lymphoma
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
San Francisco, CaliforniaAges 18 years+ - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70 - NCT05768529RecruitingPhase 1/Phase 2
Study drug U16 for relapsed or refractory CD20 lymphoma
This trial tests U16 in people with CD20-positive non-Hodgkin lymphoma that has come back or not responded after prior treatments. It may help your immune system attack the lymphoma, and researchers will check safety and early signs of benefit.
Changsha, HunanAges 18–70 - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT03125642RecruitingPhase 2
Auto stem cell transplant for lymphoma after chemo
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Minneapolis, MinnesotaAges Up to 75 years - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT05950165RecruitingPhase 1/Phase 2
Study of CHO-H01 for certain relapsed lymphoma, alone or with lenalidomide
This trial tests CHO-H01 (an anti-cancer medicine targeting CD20) to see if it is safe and effective in people with relapsed or refractory non-Hodgkin’s lymphoma. In one part of the study it may be used alone, and in another part it may be combined with lenalidomide to improve results.
Taipei, TaipeiAges 18 years+ - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT07456371RecruitingPhase 1
PIC1 injection for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Wuhan, HubeiAges 18–75 - NCT04961515RecruitingPhase 2
Orelabrutinib with immunotherapy and temozolomide for CNS lymphoma
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hangzhou, ZhejiangAges 18–75 - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed large b-cell lymphoma?
- Yes. Clin2 currently lists 239 recruiting relapsed large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.